Status:
COMPLETED
Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers
Lead Sponsor:
Concert Pharmaceuticals
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This study will assess the safety and pharmacokinetic (PK) profile of single ascending doses of CTP-692 in healthy volunteers.
Eligibility Criteria
Inclusion
- Healthy adult males and females between 18 and 55 years of age, inclusive
- Body weight ≥ 55 kg and BMI within the range of 18 to 32 kg/m2, inclusive
Exclusion
- Screening laboratory measurements outside the normal range associated with potential risk for the treatment under investigation at screening and/or prior to the first dose of study drug
- Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen or hepatitis C virus antibody
- History of clinically significant central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal (GI) conditions
- Positive drug or alcohol test at screening or prior to the first dose of study drug
Key Trial Info
Start Date :
January 24 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 28 2019
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT03830463
Start Date
January 24 2019
End Date
March 28 2019
Last Update
June 13 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Collaborative Neuroscience Network, LLC
Long Beach, California, United States, 90806